The ocular hypotensive efficacy of topical fasudil, a rho-associated protein kinase inhibitor, in patients with end-stage glaucoma

American Journal of Therapeutics

Volumn 24, Issue 6, 2016, Pages E676-E680

  Pakravan, Mohammad ^a   Beni, Afsaneh Naderi ^b   Ghahari, Elham ^b   Varshochian, Reyhaneh ^c   Yazdani, Shahin ^b   Esfandiari, Hamed ^b   Ahmadieh, Hamid ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Glaucoma; Intraocular pressure; ROCK inhibitors

Indexed keywords

FASUDIL; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; EYE DROPS; PROTEIN KINASE INHIBITOR; RHO KINASE;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; BULBAR CONJUNCTIVA; CASE STUDY; CENTRAL CORNEAL THICKNESS; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA; DRUG EFFECT; END STAGE PRIMARY OPEN ANGLE GLAUCOMA; EYE IRRITATION; FEMALE; GENERAL CONDITION; GLAUCOMATOUS OPTIC NEUROPATHY; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TOPICAL TREATMENT; TREATMENT DURATION; VASODILATATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CONJUNCTIVA; DOUBLE BLIND PROCEDURE; HYPEREMIA; INTRAOCULAR DRUG ADMINISTRATION; OCULOPLETHYSMOGRAPHY; VASCULARIZATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADMINISTRATION, OPHTHALMIC; AGED; CONJUNCTIVA; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; TONOMETRY, OCULAR;

EID: 84955619852     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000362     Document Type: Article

References (28)

1. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: The Baltimore eye survey. Arch Ophthalmol. 1991;109: 1090-1095.
2. Coleman A, Bacharach J, Miller EG, et al. Primary openangle glaucoma suspect. Glaucoma: Practicing Ophthalmologists Curriculum. San Francisco, CA: American Academy of Ophthalmology. 2007.
3. Kiland JA, Gabelt B, Tand Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004;78:639-651.
4. Tian B, Gabelt BT, Geiger B, et al. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res. 2009;8:713.
5. Liu X, Cai S, Glasser A, et al. Effect of H-7 on cultured human trabecular meshwork cells. Mol Vis. 2001;7: 145-153.
6. Tian B, Wang RF, Podos SM, et al. Effects of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys. Arch Ophthalmol. 2004;122:1171-1177.
7. Tian B, Kaufman PL. Effects of the Rho-kinase inhibitor, Y-27632, and the phosphatase inhibitor, calyculin A, on outflow facility in monkeys. Exp Eye Res. 2005;80: 215-225.
8. Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol. 2001; 119:1171-1178.
9. Rao PV, Deng PF, Kumar J, et al. Modulation of aqueoushumor outflow facility by the Rho-kinase-specific inhibitor, Y-27632. Invest Ophthalmol Vis Sci. 2001;42: 1029-1037.
10. Rosenthal R, Choritz L, Schlott S, et al. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res. 2005;80:837-845.
11. Nelson L, Goldfrank L. Goldfrank's Toxicologic Emergencies. 9th ed. New York, NY: McGraw-Hill Medical. 2011. 803.
12. Williams RD, Novack GD, van Haarlem T, et al. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834-841.
13. Wirostko BM, Umeno H, Hsu HH, et al. Safety and efficacy of a novel topical Rho kinase inhibitor ATS907 in normotensive cynomolgus monkeys. Invest Ophthalmol Vis Sci. 52, e-Abstract 3096 (2011).
14. Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309-315.
15. Tanihara H, Inoue T, Yamamoto T, et al; K-115 Clinical Study Group. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131: 1288-1295.
16. Tanihara H, Inoue T, Yamamoto T, et al; K-115 Clinical Study Group. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156: 731-736.
17. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
18. Arnold JJ, Hansen MS, Gorman GS, et al. The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate. Invest Ophthalmol Vis Sci. 2013;54: 1118-1126.
19. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov. 2012;11: 541-559.
20. Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011:667-677.
21. Kengatharan M, Wirostko B, Umeno H, et al. Pharmaceutical profile of a novel rho kinase (rock) inhibitor ats907 for reduction of iop in glaucoma. Paper presented at: Association for Research in Vision and Ophthalmology (ARVO) 2011 Annual Meeting; May 3, 2012; Fort Lauderdale, FL.
22. Bao W, Hu E, Tao L, et al. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res. 2004;61:548-558.
23. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242-248.
24. Hitomi A, Satoh S, Ikegaki I, et al. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci. 2000;67:1929-1939.
25. Jung CH, Lee WJ, Hwang JY, et al. The role of Rho/Rhokinase pathway in the expression of ICAM-1 by linoleic acid in human aortic endothelial cells. Inflammation. 2012; 35:1041-1048.
26. Anwar KN, Fazal F, Malik AB, et al. RhoA/Rho-associated kinase pathway selectively regulates thrombininduced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol. 2004;173: 6965-6972.
27. Guo F, Zhou Z, Dou Y, et al. GEF-H1/RhoA signalling pathway mediates lipopolysaccharide-induced intercellular adhesion molecular-1 expression in endothelial cells via activation of p38 and NF-kB. Cytokine. 2012;57:417-428.
28. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. 2005;36:2251-2257.